Immunosuppression in clinical practice: approaches to individualized therapy (Q37419043)

20 August 2017

1 reference

title

Immunosuppression in clinical practice: approaches to individualized therapy (English)

1 reference

20 August 2017

1 reference

3

Nicolas von Ahsen

0 references

Olaf Stüve

series ordinal

2

object named as

Olaf Stüve

1 reference

20 August 2017

Andrew Chan

1

1 reference

PubMed ID

19300956

20 August 2017

Nicolas von Ahsen

series ordinal

3

1 reference

20 August 2017

1 December 2008

1 reference

20 August 2017

1 reference

20 August 2017

255 Suppl 6

1 reference

20 August 2017

22-27

1 reference

https://scigraph.springernature.com/pub.10.1007/s00415-008-6005-y

20 August 2017

0 references

cites work

Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-008-6005-Y

CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-008-6005-Y

Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies.

21 January 2018

1 reference

12 December 2020

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.

1 reference

12 December 2020

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

1 reference

12 December 2020

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

12 December 2020

Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta

1 reference

12 December 2020

Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta

1 reference

12 December 2020

Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro

1 reference

12 December 2020

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

1 reference

12 December 2020

Multiple sclerosis registry in Germany: results of the extension phase 2005/2006

1 reference

12 December 2020

Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data

1 reference

12 December 2020

Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase

1 reference

12 December 2020

The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis

1 reference

12 December 2020

The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis. An applied study in 65 patients

1 reference

12 December 2020

Combination therapies in multiple sclerosis

1 reference

12 December 2020

Pharmacogenomics and individualized drug therapy

1 reference

12 December 2020

Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG]

1 reference

12 December 2020

Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group

1 reference

12 December 2020

Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis

1 reference

12 December 2020

Treatment of multiple sclerosis by Azathioprine. About 77 cases studied during 10 years (author's transl)

1 reference

12 December 2020

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects

1 reference

12 December 2020

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

1 reference

12 December 2020

Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis.

1 reference

12 December 2020

Escalating immunotherapy of multiple sclerosis--new aspects and practical application.

1 reference

12 December 2020

Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane

1 reference

12 December 2020

Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity

1 reference

12 December 2020

Azathioprine for multiple sclerosis

1 reference

12 December 2020

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

1 reference

12 December 2020

The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico.

1 reference

12 December 2020

Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis

1 reference

12 December 2020

Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone

1 reference

12 December 2020

Drug resistance in brain diseases and the role of drug efflux transporters.

1 reference

12 December 2020

Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.

1 reference

12 December 2020

Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study

1 reference

12 December 2020

Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine

1 reference

12 December 2020

Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.

1 reference

12 December 2020

A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine

1 reference

12 December 2020

Immunosuppression: promises and failures

1 reference

12 December 2020

Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician

1 reference

12 December 2020

A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis

1 reference

12 December 2020

Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis.

1 reference

12 December 2020

The pharmacogenetics of methotrexate

1 reference

12 December 2020

Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients

1 reference

12 December 2020

10.1007/S00415-008-6005-Y

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19300956